Literature DB >> 22581006

Late stage erythroid precursor production is impaired in mice with chronic inflammation.

Olivier D Prince1, Jacqueline M Langdon, Andrew J Layman, Ian C Prince, Miguel Sabogal, Howard H Mak, Alan E Berger, Chris Cheadle, Francis J Chrest, Qilu Yu, Nancy C Andrews, Qian-Li Xue, Curt I Civin, Jeremy D Walston, Cindy N Roy.   

Abstract

BACKGROUND: We and others have shown previously that over-expression of hepcidin antimicrobial peptide, independently of inflammation, induces several features of anemia of inflammation and chronic disease, including hypoferremia, sequestration of iron stores and iron-restricted erythropoiesis. Because the iron-restricted erythropoiesis evident in hepcidin transgenic mice differs from the normocytic, normochromic anemia most often observed in anemia of inflammation, we tested the hypothesis that chronic inflammation may contribute additional features to anemia of inflammation which continue to impair erythropoiesis following the acute phase of inflammation in which hepcidin is active. DESIGN AND METHODS: We compared erythropoiesis and iron handling in mice with turpentine-induced sterile abscesses with erythropoiesis and iron handling in hepcidin transgenic mice. We compared erythrocyte indices, expression of genes in the hepcidin regulatory pathway, tissue iron distribution, expression of heme and iron transport genes in splenic macrophages, the phenotype of erythroid maturation and chloromethyl dichlorodihydrofluorescein diacetate, acetyl ester fluorescence.
RESULTS: Mice with sterile abscesses exhibited an intense, acute inflammatory phase followed by a mild to moderate chronic inflammatory phase. We found that erythrocytes in mice with sterile abscesses were normocytic and normochromic in contrast to those in hepcidin transgenic mice. We also observed that although hypoferremia resolved in the late phases of inflammation, erythropoiesis remained suppressed, with evidence of inefficient maturation of erythroid precursors in the bone marrow of mice with sterile abscesses. Finally, we observed increased oxidative stress in erythroid progenitors and circulating erythrocytes of mice with sterile abscesses which was not evident in hepcidin transgenic mice.
CONCLUSIONS: Our results suggest that chronic inflammation inhibits late stages of erythroid production in the turpentine-induced sterile abscess model and induces features of impaired erythropoiesis which are distinct from those in hepcidin transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581006      PMCID: PMC3487436          DOI: 10.3324/haematol.2011.053397

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  40 in total

1.  Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts.

Authors:  M Socolovsky; H Nam; M D Fleming; V H Haase; C Brugnara; H F Lodish
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

2.  Storage iron kinetics. VI. The effect of inflammation on iron exchange in the rat.

Authors:  C Hershko; J D Cook; C A Finch
Journal:  Br J Haematol       Date:  1974-09       Impact factor: 6.998

3.  Effect of inflammation on erythroid precursors (BFU-E and CFU-E) in bone marrow and spleen of mice.

Authors:  K R Reissmann; K B Udupa
Journal:  J Lab Clin Med       Date:  1978-07

4.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

5.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.

Authors:  Gaël Nicolas; Caroline Chauvet; Lydie Viatte; Jean Louis Danan; Xavier Bigard; Isabelle Devaux; Carole Beaumont; Axel Kahn; Sophie Vaulont
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

6.  SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness.

Authors:  Jeffrey S Friedman; Mary F Lopez; Mark D Fleming; Alicia Rivera; Florent M Martin; Megan L Welsh; Ashleigh Boyd; Susan R Doctrow; Steven J Burakoff
Journal:  Blood       Date:  2004-06-17       Impact factor: 22.113

7.  Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).

Authors:  Karin E Finberg; Matthew M Heeney; Dean R Campagna; Yeşim Aydinok; Howard A Pearson; Kip R Hartman; Mary M Mayo; Stewart M Samuel; John J Strouse; Kyriacos Markianos; Nancy C Andrews; Mark D Fleming
Journal:  Nat Genet       Date:  2008-04-13       Impact factor: 38.330

Review 8.  New insights into erythropoiesis: the roles of folate, vitamin B12, and iron.

Authors:  Mark J Koury; Prem Ponka
Journal:  Annu Rev Nutr       Date:  2004       Impact factor: 11.848

9.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.

Authors:  Elizabeta Nemeth; Seth Rivera; Victoria Gabayan; Charlotte Keller; Sarah Taudorf; Bente K Pedersen; Tomas Ganz
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.

Authors:  David A Weinstein; Cindy N Roy; Mark D Fleming; Massimo F Loda; Joseph I Wolfsdorf; Nancy C Andrews
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

View more
  24 in total

1.  Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age.

Authors:  Bryan J McCranor; Jacqueline M Langdon; Olivier D Prince; Laurette K Femnou; Alan E Berger; Chris Cheadle; Curt I Civin; Airie Kim; Seth Rivera; Tomas Ganz; Sophie Vaulont; Qian-Li Xue; Jeremy D Walston; Cindy N Roy
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

2.  Sequestration and scavenging of iron in infection.

Authors:  Nermi L Parrow; Robert E Fleming; Michael F Minnick
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

3.  Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation.

Authors:  Claire Mayeur; Starsha A Kolodziej; Amy Wang; Xin Xu; Arthur Lee; Paul B Yu; John Shen; Kenneth D Bloch; Donald B Bloch
Journal:  Haematologica       Date:  2014-10-17       Impact factor: 9.941

4.  Whole blood transcriptome analysis in feedlot cattle after 35 days of supplementation with a β1-adrenergic agonist.

Authors:  Rachel M Burrack; Erin M Duffy; Dustin T Yates; Ty B Schmidt; Jessica L Petersen
Journal:  J Appl Genet       Date:  2019-11-09       Impact factor: 3.240

5.  Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells.

Authors:  Bryan J McCranor; Min Jung Kim; Nicole M Cruz; Qian-Li Xue; Alan E Berger; Jeremy D Walston; Curt I Civin; Cindy N Roy
Journal:  Blood Cells Mol Dis       Date:  2013-10-09       Impact factor: 3.039

6.  The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6.

Authors:  Claire Mayeur; Lisa K Lohmeyer; Patricio Leyton; Sonya M Kao; Alexandra E Pappas; Starsha A Kolodziej; Ester Spagnolli; Binglan Yu; Rita L Galdos; Paul B Yu; Randall T Peterson; Donald B Bloch; Kenneth D Bloch; Andrea U Steinbicker
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

7.  Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation.

Authors:  Jacqueline M Langdon; Saiah C Yates; Laurette K Femnou; Bryan J McCranor; Chris Cheadle; Qian-Li Xue; Sophie Vaulont; Curt I Civin; Jeremy D Walston; Cindy N Roy
Journal:  Am J Hematol       Date:  2014-02-24       Impact factor: 10.047

8.  Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus.

Authors:  Sara Gardenghi; Tom M Renaud; Alessandra Meloni; Carla Casu; Bart J Crielaard; Laura M Bystrom; Noa Greenberg-Kushnir; Barbra J Sasu; Keegan S Cooke; Stefano Rivella
Journal:  Blood       Date:  2013-12-19       Impact factor: 22.113

Review 9.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

10.  Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response.

Authors:  Chanté L Richardson; Lorrie L Delehanty; Grant C Bullock; Claudia M Rival; Kenneth S Tung; Donald L Kimpel; Sara Gardenghi; Stefano Rivella; Adam N Goldfarb
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.